scholarly journals Folate-targeting annonaceous acetogenins nanosuspensions: significantly enhanced antitumor efficacy in HeLa tumor-bearing mice

Drug Delivery ◽  
2018 ◽  
Vol 25 (1) ◽  
pp. 880-887 ◽  
Author(s):  
Haowen Li ◽  
Yijing Li ◽  
Hui Ao ◽  
Dongdong Bi ◽  
Meihua Han ◽  
...  
2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Ying Wang ◽  
Ke-Chun Wu ◽  
Bing-Xiang Zhao ◽  
Xin Zhao ◽  
Xin Wang ◽  
...  

The purpose of this study was to prepare a novel paclitaxel (PTX) microemulsion containing a reduced amount of Cremophor EL (CrEL) which had similar pharmacokinetics and antitumor efficacy as the commercially available PTX injection, but a significantly reduced allergic effect due to the CrEL. The pharmacokinetics, biodistribution,in vivoantitumor activity and safety of PTX microemulsion was evaluated. The results of pharmacokinetic and distribution properties of PTX in the microemulsion were similar to those of the PTX injection. The antitumor efficacy of the PTX microemulsion in OVCRA-3 and A 549 tumor-bearing animals was similar to that of PTX injection. The PTX microemulsion did not cause haemolysis, erythrocyte agglutination or simulative reaction. The incidence and degree of allergic reactions exhibited by the PTX microemulsion group, with or without premedication, were significantly lower than those in the PTX injection group (P<.01). In conclusion, the PTX microemulsion had similar pharmacokinetics and anti-tumor efficacy to the PTX injection, but a significantly reduced allergic effect due to CrEL, indicating that the PTX microemulsion overcomes the disadvantages of the conventional PTX injection and is one way of avoiding the limitations of current injection product while providing suitable therapeutic efficacy.


Oncotarget ◽  
2017 ◽  
Vol 8 (54) ◽  
pp. 92682-92698
Author(s):  
Tao Yang ◽  
Wenhui Shi ◽  
Zukereguli Wumaierniyazi ◽  
Lianlian Shan ◽  
Weiwei Miao ◽  
...  

2008 ◽  
Vol 127 (1) ◽  
pp. 41-49 ◽  
Author(s):  
Jong-Ho Kim ◽  
Yoo-Shin Kim ◽  
Kyeongsoon Park ◽  
Seulki Lee ◽  
Hae Yun Nam ◽  
...  

2016 ◽  
Vol 242 (2) ◽  
pp. 214-222 ◽  
Author(s):  
Jian-Hui Xiao ◽  
Yao Zhang ◽  
Gui-You Liang ◽  
Ru-Ming Liu ◽  
Xiao-Gang Li ◽  
...  

The antibacterial agent helvolic acid, which was isolated from the active antitumor fraction of Cordyceps taii, showed potent cytotoxicity against different human cancer cells. In the present study, the in vivo antitumor effect of helvolic acid was investigated in murine sarcoma S180 tumor-bearing mice. Doses of 10 and 20 mg/kg/day helvolic acid did not exert significant antitumor activity. Interestingly, co-administration of 10 mg/kg/day helvolic acid and 20 mg/kg/day cyclophosphamide (CTX) – a well-known chemotherapy drug – showed promising antitumor activity with a growth inhibitory rate of 70.90%, which was much higher than that of CTX alone (19.5%). Furthermore, the combination markedly prolonged the survival of tumor-bearing mice. In addition, helvolic acid enhanced the immune organ index. The protein expression levels of β-catenin, cyclin D1, and proliferating cell nuclear antigen were significantly suppressed in mice treated with 20 mg/kg/day helvolic acid and in those receiving combination therapy. Taken together, these results indicated that helvolic acid in combination with CTX showed potent in vivo synergistic antitumor efficacy, and its mechanism of action may involve the Wnt/ β-catenin signaling pathway.


2017 ◽  
Vol Volume 12 ◽  
pp. 5053-5067 ◽  
Author(s):  
Jingyi Hong ◽  
Zhonghao Sun ◽  
Yijing Li ◽  
Yifei Guo ◽  
Yonghong Liao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document